Skip to content
IP + Technology Law
Agnes Juang - Partner - Orange County

Agnes Juang, Ph.D.

Partner
Orange County
[email protected]
949-760-0404
vcard iconDownload vCard

Overview

Agnes Juang 主要致力于寻求知识产权保护，同时为制药、化学和医疗器械领域的客户提供咨询服务。擅长全球战略专利采购、专利组合发展和管理、专利战略咨询、专利性和侵权分析、尽职调查及许可。

目前主要服务于制药、储能、材料、纳米技术、聚合物、超声导管和心血管行业客户。

Agnes 拥有加州理工学院博士学位，在校期间专注半导体/液体和半导体/固体界面光电化学研究。开创了通过共价键连接形成聚合物覆盖层的方法，在维持电性能的同时防止硅表面氧化。同时，Agnes 还运用 X 射线光谱学和光电导衰减测量法，研究改性硅表面的空气稳定度。

工作经验

  • 跟随享有盛誉的美国加州中央区地方法院法官 Andrew Wistrich 进行实习

教育经历

  • 加州大学戴维斯分校（法学博士，2005 年）
  • 加州理工学院（化学博士，2003 年）
  • 加州大学圣塔芭芭拉分校（化学学士，1997 年），美国优秀大学生荣誉学会 (Phi Beta Kappa) 及国家化学荣誉学会 (Phi Lambda Upsilon) 最高荣誉

Dr. Agnes Juang provides counsel and advice to innovators seeking to protect their inventions and to grow and monetize their IP assets. Her practice includes strategic global patent procurement, portfolio development and management, patentability and infringement analysis, competitive landscape analysis, trade secret protection, IP due diligence, and licensing/agreement.

In her second decade of practice, Agnes understands not only the science behind sophisticated, cutting-edge invention, but also the means to implement an effective IP strategy to advance client’s business objectives. By focusing on aligning IP strategy with her client’s overall business plan, Agnes takes pride in helping start-ups and emerging companies build a sensible IP portfolio for investment and acquisition. For more established companies, Agnes helps them grow and leverage their IP assets to establish and expand their market share and realize material return on their investment.

Agnes represents individual inventors and businesses ranging from start-ups and emerging companies to publicly traded corporations in a variety of industries, including pharmaceutical, chemical, biotech, and medical device. In the chemical field, she has worked with polymer, energy storage, and nanotechnology. Her graduate research at Caltech involved investigating photoelectrochemical properties of semiconductor/liquid and semiconductor/solid interfaces. Appreciated by clients and colleagues alike for her deep bench of technical skills, Agnes can quickly learn and understand clients’ technologies and business. The breadth of her technical knowledge makes her well-suited for working with technologies involving multi-disciplinary fields.

Agnes joined the firm in 2005 and became a partner in 2011.

Clerk Experience

Extern for the Honorable Andrew Wistrich, U.S. District Court Central District of California

Education

  • University of California - Davis (J.D., 2005)
  • California Institute of Technology (Ph.D. Chemistry, 2003)
  • University of California - Santa Barbara (UCSB) (B.S. Chemistry, 1997), with highest honors, Phi Beta Kappa, Phi Lambda Upsilon National Honorary Chemical Society

Bar Admissions

  • State Bar of California
  • U.S. Patent and Trademark Office

Recognition

Awards & Honors

Named a “Top Author” in JD Supra’s 2019 “Readers’ Choice Awards” for Life Sciences

Affiliations

  • American Bar Association
  • Orange County Bar Association
  • Orange County Patent Law Association

News & Insights

Articles

Speeches & Seminars

  • Presenter, “Navigating the Patent Minefield,” Sino-American Biomedical & Pharmaceutical Professionals Association (SABPA) 9th Annual Biomedical Forum, Costa Mesa, CA (April 26, 2014).

  • Co-presenter, “What Businesses & Engineers Need to Know About Recent Changes in U.S. Patent Law”, American Society of Mechanical Engineers (ASME OC Section) and Sino-American Biomedical and Pharmaceuticals Professionals Association (SABPA) (November 8, 2012).

  • “Intellectual Property Considerations During Product Development,” Sino-American Biomedical & Pharmaceutical Professionals Association (SABPA) 7th Annual Biomedical Forum, UCI (April 28, 2012).

  • Presentations at the American Chemical Society National Meetings and the 13th International Conference on Photochemical Conversion and Storage of Solar Energy.

Latest Updates and News

Blog - Biotechnology
Dec 2024
Novo Nordisk Seeks to Block Compounded Versions of Diabetes / Weight Loss Drug
On October 22, 2024, Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide products (WEGOVY, OZEMPIC and RYBELUS) to be included in...
Blog - Biotechnology
Sep 2024
Science Group Sues FDA Over New Laboratory-Developed Test Rule
On August 19, 2024, the Association for Molecular Pathology (AMP) sued the FDA to challenge a new rule that allows the FDA to regulate laboratory developed tests (LDTs). The rule, which became effective on July 5, 2024, explicitly categorizes in vitro LDTs intended for clinical use as medical devices, placing such LDTs within the purview of the FDA. The complaint was filed in the Southern District of Texas. AMP’s suit follows another suit filed by a trade association, the American Clinical Laboratory Association, targeting the same rule.
Blog - Biotechnology
Jul 2024
WIPO Member States Adopt New Treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge
On May 24, 2024, member states of the World Intellectual Property Organization (WIPO) adopted a new treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge that was over 20 years in the making. Genetic resources, which can include medicinal plants, agriculture crops and animal breeds, cannot themselves be claimed as intellectual property. However, inventions developed using genetic resources can be protected, usually through patents. The stated goals of the treaty include enhancing the efficacy, transparency, and quality of the patent system and preventing patents from being granted erroneously for inventions that are not novel or inventive with regard to genetic resources and traditional knowledge.
Blog - Biotechnology
Feb 2024
Draft Framework for Exercise of March-In Rights under Bayh-Dole Act Targets High Drug Pricing
The National Institute of Standards and Technology (NIST) released for public comment a “Draft Interagency Guidance Framework for Considering the Exercise of March In-Rights” (“March-In Framework”) on December 8, 2023 following the White House’s announcement of initiatives to lower health care and prescription drug costs via competition.
Blog - Biotechnology
Dec 2023
The Federal Trade Commission Put Brand Drug Manufacturers on Notice About Improperly Listing Patents in the Orange Book and Then Followed Through With More Than 100 Patent Challenges
The Federal Trade Commission (FTC) issued a policy statement on September 14, 2023, stating that “[b]rand drug manufacturers may be harming generic competition through the improper listing of patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations, known as the ‘Orange Book.’” The FTC’s stated goal was to notify market participants of the FTC’s intent to scrutinize improper Orange Book listings to determine whether they constitute unfair methods of competition in violation of Section 5 of the Federal Trade Commission Act. On November 7, 2023, the FTC followed through on its warning by sending notice letters to more than 10 companies challenging the Orange Book listing of more than 100 patents covering products including specific asthma and other inhaler devices, Restasis multidose bottles, and epinephrine autoinjectors.
Blog - Biotechnology
Apr 2023
Teva v. GSK: The “Skinny” Label Case Pending Before the Supreme Court
On March 29, 2023, the Solicitor General of the United States asked the Supreme Court to review a Federal Circuit judgment in a Hatch-Waxman case between Teva and GSK. In its decision below, the Federal Circuit held that Teva could be held liable for inducement based on language in its “skinny label” and reinstated a $235 million jury award to GSK that the district court had set aside. The question at the heart of the case—as framed by Teva—is: “If a generic drug’s FDA-approved label carves out all of the language that the brand manufacturer has identified as covering its patented uses, can the generic manufacturer be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses?”